Disclaimer
The following content discusses the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
RenovoRx is evaluating the use of TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For RenovoCath’s Indications for Use and safety information, please visit IFU.
Learn more about how hospitals are using the TAMP™ therapy platform with the RenovoCath® device in oncology management, and participant experiences in the Phase III TIGeR-PaC clinical trial.*
A targeted drug-delivery device may help some pancreatic cancer patients get chemotherapy with fewer body-wide side effects.
CURE recently visited Hackensack Meridian Jersey Shore University Medical Center (JSUMC) to speak with Dr. Gregory Tiesi about Trans Arterial Microperfusion, or TAMP technology, and what it could mean for the future of pancreatic cancer treatment.
In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC).
For 70-year-old Roberta Luna, tending to her garden is therapy — especially trimming rosemary, its purple blooms matching the color she wears every day for pancreatic cancer awareness: purple.
Pancreatic cancer is a disease that’s often deadly, but a new treatment is showing promise at a New Jersey hospital. NBC10’s Ted Greenberg explains how it has made a difference for one man who thought he was out of options.
When 83-year-old Richard Martin was diagnosed with pancreatic cancer in 2024, he underwent 22 rounds of chemotherapy followed by radiation.
Chemotherapy’s a common treatment for pancreatic cancer. However, a clinical trial underway at UT Southwestern Medical Center is using an innovative approach to better target the cancer with added benefit for late-stage patients.
A new treatment for pancreatic cancer is being tested out in clinical trials in several states, and one North Carolina doctor called it "groundbreaking."
A Lakewood Ranch retiree is one of the first patients in the country to receive an experimental treatment for pancreatic cancer through a trial offered at Sarasota Memorial Hospital.
Last year, a 74-year old woman was diagnosed with inoperable pancreatic cancer. Her family turned to Miami Cancer Institute in their search for treatment options. Since her diagnosis, she became part of the TIGeR-PaC…
70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is…
Based on results of early studies highlighted by this patient's and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial…